araag2/HINT huggingface dataset:
Clinical trial NCT01108783 (phase 3, status: completed)
Conditions: seasonal allergic rhinitis
ICD codes: J30.2
Drugs: bilastine, desloratadine, placebo
SMILES: CCOCCN1C(=NC2=CC=CC=C12)C1CCN(CCC2=CC=C(C=C2)C(C)(C)C(O)=O)CC1, ClC1=CC2=C(C=C1)C(=C1CCNCC1)C1=C(CC2)C=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  The study disease was diagnosed on the basis of clinical criteria: Nasal symptoms
             (presence of nasal blockage, sneezing, nasal itching and rhinorrhea) and non-nasal
             symptoms (ocular itching, lacrimation, itching of ears and/or palate and ocular
             redness), as well as the skin prick test performed at the time of selection or within
             the year prior to entering.

          -  Patients with history of Seasonal Allergic Rhinitis, positive skin prick test and
             symptoms were included if they were between 12 and 70 years old, gave their informed
             consent, attended the required visits scheduled and also underwent a complete medical
             examination..

        Exclusion Criteria:

          -  Patients were excluded if they had a significant nasal abnormality which could
             interfere with the aim of the study, acute or chronic sinusitis, asthma or any
             condition, disease or hypersensitivity that could be harmed.

          -  Patients were not allowed to take forbidden medications or not comply the study
             requirements.

          -  Patients who were currently participating in or had participated in another clinical
             trial within the previous three months or were planning to travel outside of the study
             area during the course of the study were excluded.

          -  Pregnant or breast-feeding women were also excluded.

          -  Women of childbearing potential had a pregnancy test done
Clinical trial NCT00145327 (phase 3, status: completed)
Conditions: osteoporosis
ICD codes: M81.6, Z82.62, Z13.820, M81.8, Z87.310, M81.0, M80.80XS
Drugs: zoledronic acid, placebo
SMILES: OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who have received 3 infusions in the HORIZON-Pivotal Fracture (PFT) Study.

        Exclusion Criteria:

          -  Poor kidney, eye, or liver health

          -  Use of certain therapies for osteoporosis in the HORIZON-PFT study (other than the
             study medication)

          -  Abnormal calcium levels in the blood

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00184600 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: biphasic insulin aspart, insulin detemir, insulin aspart
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes

          -  Insulin naive

          -  On OAD treatment for at least 4 months with metformin, a sulphonylurea or a
             combination

          -  Body Mass Index (BMI) below or equal to 40.0 kg/m2

          -  HbA1c (glycosylated haemoglobin): 7.0%-10% (both inclusive)

        Exclusion Criteria:

          -  Proliferative retinopathy

          -  Recurrent major hypoglycaemia

          -  Cardial problems

          -  Uncontrolled hypertension

          -  Impaired hepatic or renal function
Clinical trial NCT00090259 (phase 3, status: completed)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: losartan 50 mg, losartan 150 mg
SMILES: CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1, CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Symptomatic heart failure with known or recently diagnosed intolerance of treatment
             with first-line medication for heart failure

          -  May or may not be receiving an alternative and/or additional drug treatment
Clinical trial NCT00089674 (phase 3, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: amg 162, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Other criteria also apply
Clinical trial NCT01357252 (phase 3, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: vildagliptin, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Confirmed diagnosis of T2DM by standard criteria

          2. Patients who have received a stable dose of SU for at least 12 weeks prior to Visit 1

          3. HbA1c ≥7.5% to ≤ 11.0% at Visit 1 and Visit 3 (Week -1)

          4. Age: ≥18 to ≤ 80 years at Visit 1.

          5. BMI ≥ 20 and ≤ 40 kg/m^2 at visit 1.

        Exclusion Criteria:

          1. FPG ≥ 270mg/dl (15.0 mmol/L) at Visit 1 or Visit 3 (Week -1)

          2. Severe or repetitive hypoglycemia, as defined in section 3.1, during the run-in period
             (between Visit 2 and Visit 4)

        Other protocol-defined inclusion/exclusion criteria may apply
Clinical trial NCT00430001 (phase 3, status: unknown status)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: docetaxel, vinorelbine, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Locally advanced or metastatic HER2-positive breast cancer

          -  WHO performance status < 3

        Exclusion Criteria:

          -  Chemotherapy for metastatic breast cancer or adjuvant therapy within 12 months with
             docetaxel, vinorelbine or trastuzumab

          -  Severe dyspnoea

          -  Abnormal organ function including cardiac
Clinical trial NCT00670787 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: combination pill of losartan and hydrochlorothiazide
SMILES: NS(=O)(=O)C1=C(Cl)C=C2NCNS(=O)(=O)C2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Aged 20 years or above

          -  Hypertension defined as blood pressure levels of >/=140/90mmHg or current use of blood
             pressure lowering drugs

          -  Able to commence combination therapy of angiotensin receptor antagonists and diuretics

        Exclusion Criteria:

          -  Blood pressure measurements of >/=200/120mmHg

          -  Previous serious adverse events due to angiotensin receptor antagonists or diuretics

          -  Known or possible pregnancy

          -  Known severe liver dysfunction

          -  Known severe kidney disease

          -  Known contraindication to angiotensin receptor antagonists or diuretics

          -  Taking >/=4 tablets except for angiotensin receptor antagonists

          -  ACE inhibitors, thiazide or thiazide-like diuretics in the morning

          -  Current participation in another clinical trial

          -  A high likelihood that the patient is not suitable for the study treatment
Clinical trial NCT00645372 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: risperidone, ziprasidone
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12, ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Hospitalized patients with schizophrenia

          -  Miminum PANSS score of 60 when randomized

        Exclusion Criteria:

          -  Planned, regular use of antipsyhotics within 1 week of randomization

          -  Previous treatment with risperidone that resulted in intolerance or lack of response
             to risperidone
Clinical trial NCT00437307 (phase 3, status: completed)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: topotecan
SMILES: CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women ≥18 years of age with platinum-sensitive recurrent ovarian cancer occurring at
             least six months after completion of primary standard therapy are eligible

          -  Patients with measurable or assessable lesions or CA-125 ≥ 2x ULN an Eastern
             Co-operative Oncology Group (ECOG) performance status ≤ 2

          -  All patients will provide written informed consent

        Exclusion Criteria:

          -  Patients with more than two chemotherapies in their history

          -  Progress less than six months after completion of primary standard therapy

          -  Simultaneous or planned radiation

          -  Any known hypersensitivity to topotecan, carboplatin, paclitaxel or gemcitabine

          -  Patients with infection

          -  Patients who are pregnant or breast feeding
Clinical trial NCT00556322 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: alimta or taxotere, erlotinib [tarceva]
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients >=18 years of age;

          -  histologically documented, locally advanced or recurrent or metastatic NSCLC;

          -  measurable disease;

          -  disease progression during 1-4 cycles of platinum-based chemotherapy.

        Exclusion Criteria:

          -  any other malignancies within the last 5 years;

          -  unstable systemic disease.
Clinical trial NCT01106677 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: placebo, canagliflozin, sitagliptin, metformin immediate release
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@]1(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Inclusion Criteria:

          -  All patients must have a diagnosis of T2DM and be currently treated with metformin IR

          -  Patients in the study must have a HbA1c between >=7 and <=10.5%

          -  Patients must have a fasting plasma glucose (FPG) <270 mg/dL (15 mmol/L)

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta
             cell transplantation, diabetes secondary to pancreatitis or pancreatectomy, or a
             severe hypoglycemic episode within 6 months before screening
Clinical trial NCT01245569 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease
ICD codes: J44.9, J44.1, J44.0
Drugs: foster® 100/6 µg/unit dose, seretide accuhaler® 500/50 µg/actuation
SMILES: OCC1=C(O)C=CC(=C1)C(O)CNCCCCCCOCCCCC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients aged ≥ 40 years, who have signed an Informed Consent form
             prior to initiation of any study-related procedure or once applicable written informed
             consent obtained by legal representative.

          2. Outpatients with a diagnosis of COPD and including:

               1. Smoking history of at least 10 pack years defined as [(number of cigarettes
                  smoked per day) x (number of years of smoking) / 20], both current and ex-smokers
                  are eligible.

               2. Use of bronchodilators in the previous 2 months to visit 1.

               3. Post-bronchodilator FEV1 < 60% of the predicted normal value.

               4. Post-bronchodilator FEV1/FVC < 0.7.

               5. A ≥ 5% response to a reversibility test.

               6. A Baseline Dyspnoea Index (BDI) focal score less or equal than 10 (to be met also
                  at visit 2).

          3. History of no more than one COPD exacerbation in the previous 12 months (without
             considering the last 2 months) to visit 1.

          4. A cooperative attitude and ability to be trained to the proper use of pMDI and DPI
             (Accuhaler®, circular moulded plastic inhaler) inhalers.

        Main Exclusion Criteria:

          1. Clinically relevant respiratory disorders.

          2. Current diagnosis of asthma or respiratory disorders other than COPD.

          3. Clinically significant laboratory and ECG abnormalities indicating a significant or
             unstable concomitant disease which may impact the feasibility of the results of the
             study according to investigator's judgement.

          4. Patients with COPD exacerbation in the 2 months prior to screening and during the
             study period.

          5. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic
             hypoxemia.

          6. Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and
             during the run-in period.
Clinical trial NCT00225017 (phase 3, status: completed)
Conditions: hiv infection, hyperlipidemia
ICD codes: Z21, E78.2, E78.49, E78.5
Drugs: atazanavir, current antiretroviral regimen
SMILES: CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1, CCO
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infection

          -  HIV-1 RNA < 500 copies/ml

          -  Fasting LDL cholesterol >130 mg/dl OR fasting triglycerides >200 mg/dl

          -  CD4 count >100 cells/mm

          -  Stable antiretroviral regimen for at least 12 weeks prior to study entry that includes
             a protease inhibitor (PI) with or without ritonavir boosting

        Exclusion Criteria:

          -  History of heart disease, uncontrolled hypertension, peripheral vascular disease

          -  Current non-nucleoside reverse transcriptase inhibitor (NNRTI) in the PI-containing
             regimen within 4 weeks

          -  Prior or current use of atazanavir

          -  Initiation of treatment with lipid-lowering drugs within 4 weeks prior to study entry
Clinical trial NCT00103402 (phase 3, status: completed)
Conditions: prostatitis
ICD codes: A54.22, A59.02, N41.0, N41.1, N41.4
Drugs: alfuzosin, placebo
SMILES: COC1=CC2=C(C=C1OC)C(N)=NC(=N2)N(C)CCCNC(=O)C1CCCO1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Participant has signed and dated the appropriate Informed Consent document.

          -  Participant is male.

          -  Participant is at least 18 years of age.

          -  Participant has had symptoms of discomfort or pain in the pelvic region for at least a
             six-week interval at the time of presentation.

          -  Symptoms bothersome enough to prompt a physician visit have been present for two years
             or less.

        Exclusion Criteria:

          -  Participant has evidence of facultative Gram negative or enterococcus with a value of
             greater than or equal to 1000 colony forming units (CFU) /ml in mid-stream urine
             (VB2).

          -  Participant has previously received alfuzosin (Uroxatral®), tamsulosin hydrochloride
             (Flomax®), doxazosin mesylate (Cardura®), terazosin hydrochloride (HCL) (Hytrin®), or
             other alpha-adrenergic receptor blockers for symptoms of CP/CPPS or within the past
             two years for any other reason.

          -  Participant has a history of prostate, penile, testicular, bladder, or urethral cancer
             or has undergone pelvic radiation, systemic chemotherapy, or intravesical
             chemotherapy.

          -  Participant has a history of moderate or severe hepatic impairment, severe renal
             sufficiency, severe or unstable cardiovascular (i.e. prolonged QT), respiratory,
             hematological, endocrinological, neurological or other somatic disorders.

          -  Participant has unilateral orchialgia without pelvic symptoms, active urethral
             stricture, or neurological disease or disorder affecting the bladder.

          -  Participant has uninvestigated, significant hematuria.

          -  Participant has undergone transurethral prostatectomy (TURP), transurethral incision
             of the prostate (TUIP), transurethral Incision or Resection of the Bladder Neck
             (TUIBN), transurethral microwave thermotherapy (TUMT), transurethral needle ablation
             (TUNA), balloon dilation of the prostate, open prostatectomy or any other prostate
             surgery or treatment such as cryotherapy or thermal therapy.

          -  Participant has a neurological impairment or psychiatric disorder preventing his
             understanding of consent and his ability to comply with the protocol.

          -  Participant is currently taking exclusionary medications such as potent CYP3A4
             inhibitors (i.e. ketoconazole, itraconazole, or ritonavir) or erythromycin.
Clinical trial NCT00367939 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan + amlodipine
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients (18 years or older)

          -  Females must be either post-menopausal for one year, surgically sterile or using
             effective contraceptive methods (e.g. barrier method with spermicide, intra-uterine
             device, hormonal contraceptives).

          -  Patients with moderate essential hypertension (WHO II)

        Exclusion Criteria:

          -  Severe hypertension

          -  Pregnant or nursing women

          -  Treated hypertensive patients with controlled hypertension under current therapy
             (MSDBP < 90 mmHg and MSSBP < 140 mmHg)

          -  A history of cardiovascular disease, including angina pectoris, myocardial infarction,
             coronary artery bypass graft, percutaneous transluminal coronary angioplasty,
             transient ischemic attack, stroke, and heart failure NYHA II - IV

          -  Other protocol-defined exclusion criteria may apply
Clinical trial NCT00326820 (phase 3, status: unknown status)
Conditions: breast cancer, hypercalcemia of malignancy, metastatic cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ibandronate sodium, zoledronic acid, zolendronic acid
SMILES: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically proven breast cancer

               -  Metastatic disease

               -  Previous relapsed disease in sites other than bone allowed

          -  Newly diagnosed multiple bone metastases within the past 3 months, meeting all of the
             following criteria:

               -  Painful or asymptomatic

               -  Lytic, mixed, or purely sclerotic type

               -  Radiological diagnosis

               -  IV bisphosphonate therapy indicated

          -  No CNS metastases

          -  Hormone receptor status not specified

        PATIENT CHARACTERISTICS:

          -  ECOG performance status 0-2

          -  Male or female

          -  Menopausal status not specified

          -  No known active peptic ulcer

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

          -  No active dental problems, including infection of the teeth or jawbone (maxilla or
             mandible) or dental or fixture trauma

          -  No prior or current diagnosis of osteonecrosis of the jaw, exposed bone in the mouth,
             or slow healing after dental procedures

          -  Creatinine clearance ≥ 30 mL/min

          -  Bilirubin ≤ 1.5 x upper limit of normal (ULN)

          -  AST and ALT ≤ 1.5 times ULN

          -  No history of bisphosphonate hypersensitivity

          -  Able to comply with instructions relating to oral study medications

          -  Able to take oral study medications

          -  No psychiatric illness or other condition that would preclude giving informed consent

        PRIOR CONCURRENT THERAPY:

          -  At least 6 months since prior bisphosphonate therapy

          -  At least 6 weeks since prior and no concurrent dental or jaw surgery (e.g.,
             extractions or implants)

               -  Concurrent unplanned dental extractions allowed provided study medication is
                  discontinued for 8 weeks before and after the surgery

          -  Concurrent chemotherapy and/or hormone therapy for metastatic disease allowed

          -  No concurrent medications that affect bone metabolism (e.g., calcitonin or other
             nontrial bisphosphonates)
Clinical trial NCT02563054 (phase 3, status: completed)
Conditions: gastric cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: 5-fluorouracil, capecitabine, cisplatin
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Adults 18 to 75 years of age

          -  Advanced and/or metastatic gastric cancer with at least 1 measurable lesion

        Exclusion Criteria:

          -  Uncontrolled infection

          -  Evidence of central nervous system (CNS) metastases

          -  History of other malignancy within the last 5 years, except cured basal cell cancer of
             the skin or cured in-situ cancer of the uterine cervix

          -  Radiation therapy or major surgery within 4 weeks of study drug

          -  Previous chemotherapy
Clinical trial NCT01152554 (phase 3, status: completed)
Conditions: major depressive disorder, mdd, depression
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: tc-5214, placebo
SMILES: CN[C@@]1(C)[C@@H]2CC[C@@H](C2)C1(C)C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Provision of signed and dated informed consent before initiation of any study-related
             procedures.

          -  The patient must have a clinical diagnosis of major depressive disorder (MDD) with
             inadequate response to no more than one antidepressant.

          -  Outpatient status at enrollment and randomization.

        Exclusion Criteria:

          -  Patients with a lifetime history of bipolar disorder, psychotic disorder or
             post-traumatic stress disorder.

          -  Patients with a history of suicide attempts in the past year and/or seen by the
             investigator as having a significant history of risk of suicide or homicide.

          -  Patients with significant liver, kidney, lung, heart, neurological, or any other
             medical conditions that might confound the study or put the patient at greater risk
             during study participation.